| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL PAPER |
a The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; b Loyola University Medical Center, Maywood, Illinois, USA
Correspondence: Eric L. Chang, M.D., The University of Texas M.D. Anderson Cancer Center, Division of Radiation Oncology, 1515 Holcombe Boulevard, Unit 97, Houston, Texas 77030, USA. Telephone: 713-563-2336; Fax: 713-563-2331; e-mail: echang{at}mdanderson.org
The brain, cranial nerves, leptomeninges, spinal cord, and eye compose the central nervous system (CNS) and are at risk for the development of metastases from breast cancer. Such metastases are diagnosed on the basis of clinical suspicion and substantiated by neuroimaging, resection when indicated, and sampling of cerebrospinal fluid when leptomeningeal metastasis (LM) is suspected. Treatment is aimed at palliation of symptoms and preservation of neurologic function. Historically, conventional radiation therapy has been the mainstay of palliative treatment for brain, cranial nerve, spinal cord, and ocular metastases. However, additional treatment options for brain metastases have been brought about by technological advances in surgery to resect brain metastases, and stereotactic radiosurgery (SRS) to focally irradiate metastases, both of which have been substantiated by data from randomized trials. Ongoing research is aimed at refining criteria to select which patients with brain metastases should undergo surgery and SRS and how these focal therapies should be optimally integrated with whole-brain radiotherapy. Therapy for LM must carefully balance the potential risks and perceived benefits associated with CNS-directed therapies. Despite advances in neuroimaging, surgery, and radiation therapy, novel treatments are needed to improve the effectiveness of treatments for CNS metastases, especially LM, while reducing attendant neurotoxicity.
This article has been cited by other articles:
 |
|
 |
|
  S. Gori, V. D. Angelis, M. Colozza, and L. Crino In Reply Oncologist, December 1, 2007; 12(12): 1469 - 1471. [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Kominsky, B. Tyler, J. Sosnowski, K. Brady, M. Doucet, D. Nell, J. G. Smedley III, B. McClane, H. Brem, and S. Sukumar Clostridium perfringens Enterotoxin as a Novel-Targeted Therapeutic for Brain Metastasis Cancer Res., September 1, 2007; 67(17): 7977 - 7982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Gori, S. Rimondini, V. De Angelis, M. Colozza, G. Bisagni, G. Moretti, A. Sidoni, C. Basurto, C. Aristei, P. Anastasi, et al. Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors Oncologist, July 1, 2007; 12(7): 766 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. I. Chen, J. Hewel, J. S. Krueger, C. Tiraby, M. R. Weber, A. Kralli, K. Becker, J. R. Yates III, and B. Felding-Habermann Adaptation of Energy Metabolism in Breast Cancer Brain Metastases Cancer Res., February 15, 2007; 67(4): 1472 - 1486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg Breast Cancer Metastasis to the Central Nervous System Am. J. Pathol., October 1, 2005; 167(4): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. V. Nome, A. Bratland, G. Harman, O. Fodstad, Y. Andersson, and A. H. Ree Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death Mol. Cancer Ther., August 1, 2005; 4(8): 1231 - 1238. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
